Novo introduces Ozempic in India
Digest more
Novo Nordisk ( NVO 2.28%) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic developer would want. An analyst's downgrade was the catalyst for some shareholders to exit the stock, and as a result, its price was down by more than 2% in mid-session trading.
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 (approx ₹ 2,200) per week, as it seeks to tap into the country’s rapidly expanding diabetes and obesity market, where demand for weight-loss treatments is soaring, Reuters reported.
Novo Nordisk has launched its blockbuster diabetes drug Ozempic in India, pricing the starter dose at ₹8,800 per month (₹2,200 per week), positioning it as a competitor to Eli Lilly's Mounjaro (priced at ₹14,
Novo Nordisk's appeal is listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla